查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1848739

癌症切片检查市场（按产品类型、应用、技术和最终用户）—2025-2032 年全球预测

Cancer Biopsy Market by Product Type, Application, Technology, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年癌症切片检查市场规模将成长至 867.2 亿美元，复合年增长率为 12.63%。

主要市场统计数据
基准年2024年 334.8亿美元
预计2025年 377.6亿美元
预测年份：2032年 867.2亿美元
复合年增长率（%） 12.63%

策略性地建构临床需求、设备创新和护理服务重新配置如何共同塑造跨护理环境的当代切片检查实践

本介绍将现代切片检查实践置于临床需求、技术创新和不断发展的医疗服务模式的交汇点。影像、设备和操作指南的进步正在重塑诊断工作流程，而人们对准确性、病患舒适度和周转时间的期望不断提高，也提升了微创取样技术的作用。因此，多学科团队正在重新调整通讯协定，以整合诊断准确性、通量和成本，而管理人员则优先考虑与更广泛的基于价值的医疗目标相符的模式。

随着相关人员面临劳动力限制、监管审查和付款方动态变化，对有关程序选择、技术采用和治疗部位优化的强有力证据的需求日益加剧。本执行摘要概述了影响实践模式、供应链和供应商策略的关键趋势，旨在为读者提供清晰的方向，帮助他们了解在不同临床环境中重新定义组织采集选择、执行和管理方式的潜在力量。

关键的转型变化凸显了诊断影像的进步、向门诊护理的转变以及跨学科工作流程如何重新定义切片检查实践

由于技术的日趋成熟、工作流程的重新设计以及对以患者为中心的治疗结果的日益重视，癌症切片检查领域正在发生重大变化。影像导引方法日益复杂，能够更精准地定位病灶，并减少非诊断性取样。同时，随着临床医生和管理人员力求降低成本、提高诊疗效率并改善患者体验，手术路径正从住院机构转向门诊手术和诊断影像中心。

同时，诊断方法正在融合，病理学家、放射科医生和介入科医生之间的合作更加紧密，组织采样也得到优化，以用于下游的分子和基因组检测。这种多学科整合正在影响设备设计、检体处理通讯协定和供应链安排。因此，製造商和医疗保健提供者必须调整其策略，以支援无缝的临床协作、法规遵循和品质保证，同时兼顾患者偏好和医疗机构的效率要求。

2025 年关税环境如何重塑癌症切片检查设备和耗材的筹资策略、采购弹性和服务成本模型

2025年近期关税措施的累积影响将为依赖跨境供应链采购切片穿刺针、成像硬体、耗材和辅助设备的采购团队、製造商和临床服务提供者带来层层复杂性。部分医疗设备和零件的进口关税上调将推高到岸成本，奖励企业重新评估筹资策略。这种环境将鼓励采购领导者优先考虑供应商多元化、尽可能采用近岸外包，以及能够在整个供应链中分配风险的合约结构。

在营运方面，医院和诊断中心面临严重的预算限制，可能会扩大库存池和外包安排，以缓解价格波动。为此，医疗设备製造商正在探索重新设计以替代受关税影响的零件，谈判长期供应协议，并加快替代供应商的资格审查。法规合规性和品质保证仍然是不可协商的，任何采购转变都必须保持临床性能和无菌标准。最终，关税环境促使人们重新评估成本服务模型，凸显了建立透明的供应商关係和情境规划以维持临床连续性的必要性。

细分市场主导的洞察揭示了产品、应用、技术和最终用户的差异如何推动临床选择、采购和创新重点

精细的细分视角能够清楚地理解临床需求、技术适用性和最终用户能力之间的交集，从而确定采用模式和营运优先顺序。按产品类型细分可以揭示诸如粗针穿刺切片和细针穿刺等替代方案之间的性能权衡，以及手术活检和真空辅助切片检查在不同临床场景中的相对作用。基于应用的细分可以揭示不同肿瘤部位的不同临床切片检查和检体处理需求，包括乳房、肝臟、肺部、前列腺和甲状腺手术的工作流程，这些都会影响设备的选择和诊断影像需求。

我们对终端使用者的细分也揭示了门诊手术中心、诊断影像中心、医院和诊所之间运作能力的差异。结合这些观点，可以支援有针对性的产品开发、差异化的培训项目以及商业性化方案，使设备功能与每个细分市场的临床和营运实际情况相符。

区域动态和主要地区的医疗保健服务差异影响设备采用、监管策略和临床工作流程优化

区域动态在塑造临床通讯协定、报销框架和设备可用性方面发挥着至关重要的作用，而这些因素又反过来影响采用曲线和供应商策略。美洲的医疗保健系统由私营和公共部门组成，构成复杂组合，高度重视成本控制和基于价值的治疗结果，这使得医疗服务提供者青睐那些能够提供可靠诊断结果和高效诊疗流程的诊疗程序。该地区的监管途径和报销政策也奖励采用微创诊疗程序，以减少住院时间并加快诊断速度。

欧洲、中东和非洲是一个多元化的地区，每个国家的医疗保健系统和基础设施水准都会影响技术的采用。资源丰富的市场正在迅速采用先进的影像引导和机器人辅助解决方案，而其他市场则优先考虑耐用、经济高效的设备和本地培训，以扩大覆盖范围。在亚太地区，快速的都市化、对肿瘤基础设施的投资以及大量的手术量正在推动对扩充性解决方案和整合诊断路径的需求。在所有地区，当地监管要求、供应链考量和劳动力技能将决定新切片检查技术和服务模式的实际部署。

竞争性和策略性的公司评论重点关注设备整合、证据生成和伙伴关係主导的诊断途径的创新

切片检查系统的竞争态势体现了技术差异化、战略伙伴关係关係以及专注的临床证据开发的融合。领先的公司优先投资于影像相容性、检体储存技术和整合流程平台，以简化临床工作流程并降低非诊断率。透过同侪审查研究和真实世界证据证明临床结果改善的公司能够赢得关键意见领袖和医院采购委员会的信任，从而加速机构的采用。

同时，规模较小、专业化的参与企业正在透过满足尚未满足的程序需求来开拓利基市场，例如针对难以触及的病变定制的切片检查设备，或针对分子级标本采集优化的工具。设备製造商与病理学和基因组学检测提供者之间也正在形成策略联盟，以优化从检体采集到分子分析的整个诊断流程。最后，商业策略越来越受到服务模式的影响，包括培训、程序支援和捆绑服务，这些模式有助于提供者以更低的营运摩擦采用新技术。

为製造商、医疗保健提供者和采购领导者提供实用的优先策略建议，以改善结果、降低供应风险并加速采用

设备製造、医院系统和诊断服务的领导者可以采取具体措施来提升临床疗效、营运韧性和商业性绩效。首先，投入资金，收集能够证明诊断产量比率、治疗决策和病人报告结果改善的证据。其次，制定灵活的供应结构和供应商多元化计划，以减少单一来源中断的风险，并透过寻找替代零件和近岸供应商来应对关税主导的成本压力。

第三，我们将整合介入放射学、病理学和肿瘤学团队的回馈，根据每个临床应用和最终用户的细微需求客製化产品开发。第四，我们将建立策略伙伴关係，将组织采集与下游分子检测结合，打造医疗系统重视的端到端解决方案。最后，我们将优先推动数位化，包括资料收集、工作流程整合和远端监考，以提升品质保证，并促进不同医疗机构的规模化发展。

严格的多源调查方法结合了临床医生访谈、技术设备审查和证据三角测量，确保了可靠且可操作的见解

本研究采用三角调查方法，整合质性和量性证据，强调资料的完整性和可重复性。主要研究内容包括对临床医生、采购负责人和设备工程师的结构化访谈，以了解操作偏好、设备性能权衡和实施经验。次要研究内容包括同行评审文献、监管文件、操作指南和公开的技术规范，以检验临床主张并为技术进步提供背景。

分析的严谨性透过跨资料流的方法学交叉验证、关键假设的敏感性检查以及临床专家的迭代评审来实现，以确保解释能够反映现实世界的实践。在某些情况下，案例研究和供应商提供的临床数据也会进行方法学和偏差评估，并透明地记录其局限性，以指导研究结果的合理应用。这种方法确保结论是实践者见解、设备性能证据和监管环境的均衡综合。

简要概述策略要点和营运重点，以决定哪些切片检查方法将被广泛采用并获得临床信任。

结论综合了分析中得出的关键主题：临床需求、技术进步和操作限制共同推动着人们转向更精准、侵入性更小且工作流程更便捷的活检解决方案。医疗保健决策者必须权衡流程有效性与营运考量，例如通量、切片检查负担和供应链稳定性。随着诊断途径与分子检测日益融合，检体完整性和标准化处理通讯协定将变得越来越重要。

展望未来，积极适应当地监管要求、建立策略伙伴关係关係并投资于证据生成的相关人员将最有能力影响临床实践并获取价值。创新与实用化的相互作用将决定哪些技术将被广泛采用，哪些技术仍将是利基解决方案，这凸显了在商业、临床和供应链职能部门中製定严谨的评估和适应策略的必要性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合液态生物检体检测，利用 ctDNA 和外泌体生物标记进行早期癌症检测
  • 将人工智慧驱动的影像分析引入针刺活检程序可提高诊断准确性并缩短样本处理时间
  • 开发一种能够对深层肿瘤进行精确取样的微创机器人切片检查装置
  • 扩展切片检查标本中的次世代定序面板，以指导个人化肿瘤治疗决策
  • 照护现场切片检查平台，用于门诊肿瘤科的快速分子分析
  • 结合循环性肿瘤细胞、DNA 和 RNA 的多检体液态生物检体测试的出现，可以实现全面的肿瘤表征
  • 监管核准和报销改革将加速关键市场创新切片检查技术的商业化
  • 诊断公司和学术中心之间的合作，以检验新的切片检查生物标记和通讯协定
  • 利用 cfDNA 甲基化分析进行多癌筛检，泛癌早期检测检测的兴起
  • 将人工智慧驱动的决策支援工具与切片检查基因型数据相结合，以预测患者结果和治疗反应

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章癌症切片检查市场（按产品类型）

  • 芯针切片
  • 细针穿刺法
  • 手术切片检查
  • 真空辅助切片检查

第九章 癌症切片检查市场（按应用）

  • 胸部
  • 肝
  • 肺
  • 摄护腺
  • 甲状腺

第 10 章癌症切片检查市场（按技术）

  • 影像引导切片检查
  • 徒手手动切片检查
  • 机器人辅助切片检查

第 11 章 癌症切片检查市场（按最终用户）

  • 门诊手术中心
  • 诊断影像中心
  • 医院
  • 医生办公室

第 12 章癌症切片检查市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 癌症切片检查市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 癌症切片检查市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Boston Scientific Corporation
    • Hologic, Inc.
    • Medtronic plc
    • Cardinal Health, Inc.
    • Cook Medical LLC
    • Becton, Dickinson and Company
    • Olympus Corporation
    • Argon Medical Devices, Inc.
    • Teleflex Incorporated
    • B. Braun Melsungen AG
Product Code: MRR-C27187914300

The Cancer Biopsy Market is projected to grow by USD 86.72 billion at a CAGR of 12.63% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 33.48 billion
Estimated Year [2025] USD 37.76 billion
Forecast Year [2032] USD 86.72 billion
CAGR (%) 12.63%

A strategic framing of how clinical needs, device innovation, and care delivery reconfiguration are jointly shaping modern cancer biopsy practice across care settings

The introduction positions contemporary cancer biopsy practice at the confluence of clinical imperative, technological innovation, and evolving care delivery models. Advances in imaging, instrumentation, and procedural guidance have reshaped diagnostic workflows, while heightened expectations for precision, patient comfort, and turnaround time have elevated the role of minimally invasive sampling techniques. Consequently, multidisciplinary teams are recalibrating protocols to integrate diagnostic accuracy with throughput and cost considerations, and administrators are prioritizing modalities that align with broader value-based care objectives.

As stakeholders confront workforce constraints, regulatory scrutiny, and shifting payer dynamics, the case for robust evidence on procedure choice, technology adoption, and site-of-care optimization grows stronger. Therefore, this executive summary frames the critical trends influencing practice patterns, supply chains, and vendor strategies, offering readers a clear orientation to the underlying forces redefining how tissue acquisition is selected, performed, and managed across diverse clinical settings.

Key transformative shifts revealing how imaging advances, care migration to ambulatory settings, and interdisciplinary workflows are redefining biopsy practice

The landscape of cancer biopsy is undergoing transformative shifts driven by technological maturation, workflow redesign, and a heightened emphasis on patient-centered outcomes. Imaging-guided approaches have become more sophisticated, enabling more precise targeting of lesions and reducing non-diagnostic sampling, while robotics and automation are beginning to emerge in select centers to improve reproducibility and safety. Meanwhile, procedural pathways are migrating from inpatient settings to ambulatory surgical centers and diagnostic imaging centers as clinicians and administrators seek to lower costs, improve throughput, and enhance patient experience.

In parallel, there is a convergence of diagnostic modalities, with pathologists, radiologists, and interventionalists collaborating more closely to ensure that tissue sampling is optimized for downstream molecular and genomic testing. This interdisciplinary integration is influencing device design, specimen handling protocols, and supply chain arrangements. As a result, manufacturers and providers must adapt their strategies to support seamless care coordination, regulatory compliance, and quality assurance, all while addressing patient preferences and institutional efficiency mandates.

How the 2025 tariff environment is reshaping sourcing strategies, procurement resilience, and cost-to-serve models for devices and consumables used in cancer biopsy

The cumulative impact of recent tariff actions in 2025 introduces a layer of complexity for procurement teams, manufacturers, and clinical providers that rely on cross-border supply chains for biopsy needles, imaging hardware, disposables, and accessory devices. Increased import duties on select medical devices and components amplify landed costs and create incentives for firms to reassess sourcing strategies. This environment encourages procurement leaders to prioritize supplier diversification, nearshoring where feasible, and contract structures that allocate risk across the supply chain.

Operationally, hospitals and diagnostic centers face tighter budgetary constraints and may extend inventory pooling and consignment arrangements to mitigate price volatility. In response, device makers are exploring redesigns that substitute tariff-exposed components, negotiating long-term supply agreements, and accelerating qualification of alternative suppliers. Regulatory compliance and quality assurance remain non-negotiable, so any sourcing pivot must preserve clinical performance and sterility standards. Ultimately, the tariff environment is prompting a re-evaluation of cost-to-serve models, while underscoring the need for transparent supplier relationships and scenario planning to maintain clinical continuity.

Segment-driven insights revealing how product, application, technology, and end-user differences drive clinical choice, procurement, and innovation priorities

A granular segmentation lens clarifies where clinical demand, technology fit, and end-user capabilities intersect to determine adoption patterns and operational priorities. Product Type distinctions illuminate performance trade-offs between alternatives such as Core Needle Biopsy versus Fine Needle Aspiration, and the relative roles of Surgical Biopsy and Vacuum-Assisted Biopsy in different clinical scenarios; these modalities differ in sample volume, diagnostic yield, and procedural setting requirements. Application-based segmentation highlights unique clinical pathways and specimen handling demands across tumor sites, including distinct workflows for Breast, Liver, Lung, Prostate, and Thyroid procedures that influence device selection and imaging needs.

Technology segmentation underscores the implications of Imaging Guided Biopsy compared with Manual Freehand Biopsy and the emerging role of Robotic Assisted Biopsy in enhancing precision and reproducibility, while end-user segmentation reveals how operational capabilities vary across Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, and Physicians Offices. When combined, these perspectives support targeted product development, differentiated training programs, and tailored commercial approaches that align device features with the clinical and operational realities of each segment.

Regional dynamics and care delivery variations across major geographies that influence device adoption, regulatory strategy, and clinical workflow optimization

Regional dynamics play a decisive role in shaping clinical protocols, reimbursement frameworks, and device availability, which in turn influence adoption curves and vendor strategies. In the Americas, healthcare systems span complex private and public mixes with strong emphasis on cost containment and value-based outcomes, prompting providers to favor procedures that deliver robust diagnostic yield with efficient throughput. Regulatory pathways and reimbursement policies in this region also incentivize adoption of minimally invasive techniques that reduce length of stay and expedite diagnosis.

Europe, Middle East & Africa present a heterogeneous landscape where national health systems and varying levels of infrastructure affect technology diffusion. In higher-resource markets, there is rapid uptake of advanced imaging-guided and robotic-assisted solutions, whereas other markets prioritize durable, cost-effective devices and local training to expand access. In Asia-Pacific, rapid urbanization, investments in oncology infrastructure, and high procedural volumes drive demand for scalable solutions and integrated diagnostic pathways. Across all regions, local regulatory requirements, supply chain considerations, and workforce skills shape the practical rollout of new biopsy technologies and service models.

Competitive and strategic company insights highlighting innovation in device integration, evidence generation, and partnership-driven diagnostic pathways

Competitive dynamics in the biopsy ecosystem reflect a blend of technological differentiation, strategic partnerships, and focused clinical evidence development. Leading firms are prioritizing investments in imaging compatibility, specimen preservation technologies, and integrated procedural platforms that streamline clinician workflows and reduce non-diagnostic rates. Companies that demonstrate clinical outcomes improvements through peer-reviewed studies and real-world evidence gain credibility with key opinion leaders and hospital procurement committees, thereby accelerating institutional adoption.

At the same time, smaller, specialized entrants are carving niches by addressing unmet procedural needs, such as biopsy devices tailored for difficult-to-access lesions or tools optimized for molecular-grade specimen collection. Strategic collaborations between device makers and pathology or genomic testing providers are emerging to ensure that the entire diagnostic pathway, from tissue acquisition to molecular analysis, is optimized. Finally, commercial strategy is increasingly informed by service models-training, procedural support, and bundled offerings-that help providers adopt new technologies with lower operational friction.

Practical and prioritized strategic recommendations for manufacturers, providers, and procurement leaders to improve outcomes, mitigate supply risk, and accelerate adoption

Leaders in device manufacturing, hospital systems, and diagnostic services can take concrete steps to strengthen clinical outcomes, operational resilience, and commercial performance. First, invest in evidence generation that demonstrates improvements in diagnostic yield, downstream treatment decision-making, and patient-reported outcomes; such data supports procurement discussions and clinician acceptance. Second, develop flexible supply arrangements and supplier diversification plans that reduce exposure to single-source disruptions and respond to tariff-driven cost pressures by qualifying alternative components and nearshore suppliers.

Third, align product development with the nuanced needs of each clinical application and end user by incorporating feedback from interventional radiology, pathology, and oncology teams; tailoring training and onboarding reduces implementation risk. Fourth, pursue strategic partnerships that integrate tissue acquisition with downstream molecular testing to create end-to-end solutions valued by health systems. Finally, prioritize digital enablement-data capture, workflow integration, and remote proctoring-to improve quality assurance and facilitate scale across disparate sites of care.

A rigorous, multi-source research methodology combining clinician interviews, device technical review, and evidence triangulation to ensure credible and actionable insights

The study synthesizes qualitative and quantitative evidence using a triangulated research approach that emphasizes data integrity and reproducibility. Primary inputs include structured interviews with clinicians, procurement leaders, and device engineers to capture procedural preferences, device performance trade-offs, and implementation experience. Secondary research encompasses peer-reviewed literature, regulatory filings, procedural guidelines, and publicly available technical specifications to validate clinical claims and contextualize technological advances.

Analytical rigor is achieved through methodical cross-validation across data streams, sensitivity checks on key assumptions, and iterative review by clinical experts to ensure that interpretations reflect frontline practice. Where applicable, case studies and vendor-provided clinical data are assessed for methodology and bias, and limitations are transparently documented to guide appropriate application of findings. This methodology ensures that conclusions rest on a balanced synthesis of practitioner insight, device performance evidence, and regulatory context.

A concise synthesis of strategic imperatives and operational priorities that will determine which biopsy approaches gain broad adoption and clinical trust

The conclusion synthesizes the dominant themes that emerged from the analysis: that clinical imperatives, technological evolution, and operational constraints are jointly driving a shift toward more precise, less invasive, and more workflow-friendly biopsy solutions. Institutional decision-makers must weigh procedural efficacy against operational considerations such as throughput, training burden, and supply chain stability. As diagnostic pathways become increasingly integrated with molecular testing, the importance of specimen integrity and standardized handling protocols will grow.

Looking ahead, stakeholders who proactively adapt to regional regulatory requirements, engage in strategic partnerships, and invest in evidence generation will be best positioned to influence clinical practice and capture value. The interplay between innovation and practical implementation will determine which technologies achieve broad adoption and which remain niche solutions, underscoring the need for disciplined evaluation and adaptive strategies across commercial, clinical, and supply chain functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of liquid biopsy assays for early cancer detection using ctDNA and exosomal biomarkers
  • 5.2. Adoption of AI-driven image analysis in needle biopsy procedures to enhance diagnostic accuracy and reduce sample processing times
  • 5.3. Development of minimally invasive robotic biopsy devices enabling precision sampling of deep-seated tumors
  • 5.4. Expansion of next-generation sequencing panels in biopsy specimens to guide personalized oncology treatment decisions
  • 5.5. Growth of point-of-care biopsy diagnostic platforms for rapid molecular profiling in outpatient oncology settings
  • 5.6. Emergence of multianalyte liquid biopsy tests combining circulating tumor cells, DNA, and RNA for comprehensive tumor characterization
  • 5.7. Regulatory approvals and reimbursement reforms driving commercialization of innovative biopsy technologies in major markets
  • 5.8. Collaborations between diagnostic companies and academic centers to validate novel biopsy biomarkers and protocols
  • 5.9. Rise of pan-cancer early detection assays leveraging cfDNA methylation profiling for multi-cancer screening
  • 5.10. Integration of AI-driven decision support tools with biopsy genotyping data to predict patient outcomes and therapy response

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biopsy Market, by Product Type

  • 8.1. Core Needle Biopsy
  • 8.2. Fine Needle Aspiration
  • 8.3. Surgical Biopsy
  • 8.4. Vacuum-Assisted Biopsy

9. Cancer Biopsy Market, by Application

  • 9.1. Breast
  • 9.2. Liver
  • 9.3. Lung
  • 9.4. Prostate
  • 9.5. Thyroid

10. Cancer Biopsy Market, by Technology

  • 10.1. Imaging Guided Biopsy
  • 10.2. Manual Freehand Biopsy
  • 10.3. Robotic Assisted Biopsy

11. Cancer Biopsy Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
  • 11.4. Physicians Offices

12. Cancer Biopsy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Biopsy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Biopsy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Boston Scientific Corporation
    • 15.3.2. Hologic, Inc.
    • 15.3.3. Medtronic plc
    • 15.3.4. Cardinal Health, Inc.
    • 15.3.5. Cook Medical LLC
    • 15.3.6. Becton, Dickinson and Company
    • 15.3.7. Olympus Corporation
    • 15.3.8. Argon Medical Devices, Inc.
    • 15.3.9. Teleflex Incorporated
    • 15.3.10. B. Braun Melsungen AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOPSY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. AMERICAS CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 113. AMERICAS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. AMERICAS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 117. AMERICAS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 119. AMERICAS CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 128. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 130. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 136. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. EUROPE CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. EUROPE CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. EUROPE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. EUROPE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPE CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPE CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 174. AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 175. AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 177. AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 178. AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 179. AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 180. AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. ASEAN CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. ASEAN CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. ASEAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. ASEAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. ASEAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 198. ASEAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 199. ASEAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 200. ASEAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 201. ASEAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. ASEAN CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. GCC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GCC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GCC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. GCC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. GCC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. GCC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. GCC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 210. GCC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 211. GCC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. GCC CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 223. BRICS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. BRICS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. BRICS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. BRICS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. BRICS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. BRICS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. BRICS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. BRICS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 231. BRICS CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. BRICS CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. G7 CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. G7 CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. G7 CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. G7 CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. G7 CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 238. G7 CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 239. G7 CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 240. G7 CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 241. G7 CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. G7 CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NATO CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NATO CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NATO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NATO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NATO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. NATO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NATO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. NATO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 251. NATO CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. NATO CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. UNITED STATES CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED STATES CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. UNITED STATES CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED STATES CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. UNITED STATES CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED STATES CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. CANADA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. CANADA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. CANADA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. CANADA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. CANADA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. CANADA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. CANADA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 270. CANADA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 271. MEXICO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MEXICO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MEXICO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. MEXICO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 275. MEXICO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. MEXICO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. MEXICO CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. MEXICO CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. BRAZIL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRAZIL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. BRAZIL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. BRAZIL CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 291. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED KINGDOM CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. GERMANY CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GERMANY CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. GERMANY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. GERMANY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. GERMANY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 300. GERMANY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 301. GERMANY CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. GERMANY CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. FRANCE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. FRANCE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. FRANCE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. FRANCE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 307. FRANCE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. FRANCE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. FRANCE CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 310. FRANCE CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 311. RUSSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. RUSSIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. RUSSIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 314. RUSSIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 315. RUSSIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 316. RUSSIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 317. RUSSIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. RUSSIA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. ITALY CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. ITALY CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. ITALY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. ITALY CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 323. ITALY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 324. ITALY CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 325. ITALY CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. ITALY CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 327. SPAIN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. SPAIN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. SPAIN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 330. SPAIN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 331. SPAIN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 332. SPAIN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 333. SPAIN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. SPAIN CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. CHINA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. CHINA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. CHINA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 338. CHINA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 339. CHINA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 340. CHINA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 341. CHINA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. CHINA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. INDIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. INDIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 345. INDIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 346. INDIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 347. INDIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 348. INDIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 349. INDIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. INDIA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 351. JAPAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. JAPAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 353. JAPAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 354. JAPAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 355. JAPAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 356. JAPAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 357. JAPAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 358. JAPAN CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 359. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 360. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 361. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 362. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 363. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 364. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 365. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 366. AUSTRALIA CANCER BIOPSY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 367. SOUTH KOREA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 201